Probiotics improve the efficacy of standard triple therapy in the eradication of Helicobacter pylori: a meta-analysis

Christine S M Lau1,2
Amanda Ward3
Ronald S Chamberlain1–4

1Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ, USA; 2Saint George’s University School of Medicine, Grenada, West Indies; 3Department of Surgery, Banner MD Anderson Cancer Center, Gilbert, AZ, USA; 4Department of Surgery, New Jersey Medical School, Rutgers University, Newark, NJ, USA

Methods: A comprehensive literature search was conducted using PubMed, Cochrane Central Registry of Controlled Trials, and Google Scholar (time of inception to 2016) to identify all published randomized control trials (RCTs) assessing the use of probiotics in addition to triple therapy for the treatment of H. pylori. Searches were conducted using the keywords “probiotics”, “triple therapy”, and “Helicobacter pylori”. RCTs comparing the use of probiotics and standard triple therapy with standard triple therapy alone for any duration in patients of any age diagnosed with H. pylori infection were included. H. pylori eradication rates (detected using urea breath test or stool antigen) were analyzed as-per-protocol (APP) and intention-to-treat (ITT).

Results: A total of 30 RCTs involving 4,302 patients APP and 4,515 patients ITT were analyzed. The addition of probiotics significantly increased eradication rates by 12.2% (relative risk [RR] = 1.122; 95% confidence interval [CI], 1.091–1.153; P<0.001) APP and 14.1% (RR = 1.141; 95% CI, 1.06–1.175; P<0.001) ITT. Probiotics were beneficial among children and adults, as well as Asians and non-Asians. No significant difference was observed in efficacy between the various types of probiotics. The risk of diarrhea, nausea, vomiting, and epigastric pain was also reduced.

Conclusion: The addition of probiotics is associated with improved H. pylori eradication rates in both children and adults, as well as Asians and non-Asians. Lactobacillus, Bifidobacterium, Saccharomyces, and mixtures of probiotics appear beneficial in H. pylori eradication. Furthermore, the reduction in antibiotic-associated side effects such as nausea, vomiting, diarrhea, and epigastric pain improves medication tolerance and patient compliance. Given the consequences associated with chronic H. pylori infection, the addition of probiotics to the concurrent triple therapy regimen should be considered in all patients with H. pylori infection. However, further studies are required to identify the optimal probiotic species and dose.

Keywords: probiotics, Helicobacter pylori, triple therapy, meta-analysis

Introduction

Helicobacter pylori, previously referred to as Campylobacter pylori, is a Gram-negative, spiral bacterium that is present on the gastric epithelium mucus layer.1 H. pylori colonization almost always leads to acute gastritis, with neutrophilic and mononuclear...
infiltrates in the gastric mucosa. If left untreated, it can cause chronic gastritis, which is associated with various gastrointestinal diseases. Various extragastric manifestations of *H. pylori* have also been reported, including idiopathic thrombocytopenia purpura, vitamin B12 deficiency, and metabolic syndrome. Studies have reported *H. pylori* colonization to be as high as 90% among patients with gastric ulcers or cancer. Furthermore, virtually, all patients with mucosa-associated lymphoid tissue lymphomas (MALTomas) are colonized with *H. pylori*. It is estimated that over half of the current world population has *H. pylori* in their gastric flora. Early *H. pylori* eradication has been associated with a sixfold reduction in the recurrence of ulcers as well as a two- to threefold reduction in the risk of gastric carcinoma.

Current treatment guidelines recommend concomitant triple therapy for the eradication of *H. pylori*, utilizing clarithromycin, either amoxicillin or metronidazole, as well as a proton pump inhibitor for 7–14 days. Despite initial successes, there has been a constant decline in *H. pylori* eradication rates with standard triple therapy in both adult and pediatric populations, from 75 to 55% between 2009 and 2014. Although several mechanisms have been proposed, most of the studies agree that the main reasons for the declining efficacy are the increasing resistance to clarithromycin and poor medication compliance as a result of antibiotic-induced nausea, vomiting, and diarrhea. While eradication rates of 88% are seen with clarithromycin-sensitive *H. pylori* strains, eradication rates are only 14% among strains resistant to clarithromycin. As with all antibiotics, *H. pylori* medications often cause diarrhea, nausea, and vomiting, which lead to poor tolerance and ultimately decreased patient compliance, the single most important factor in *H. pylori* eradication. Graham et al reported *H. pylori* eradication rates of 96% in high medication-compliant patients (taking ≥60% of the prescribed antibiotics), while only 69% eradication rates were observed among low medication-compliant patients (taking <60% of prescribed antibiotics). With the decline in *H. pylori* eradication rates, novel therapeutic alternatives are being studied and evaluated. Eradication rates are highest during the early phase of treatment when antibiotic sensitivity and patient compliance are greatest. Early treatment failure results in elevated risk of secondary antibiotic resistance due to the need for additional, less effective antibiotics used over longer periods of time with the possibility of additional medication side effects, thereby perpetuating the increase in antibiotic resistance and decreased medication compliance cycle. Since medication compliance has been considered the most important factor in *H. pylori* eradication, a major goal of therapy is aimed at improving the compliance. Recently, the use of probiotic supplementation has been proposed for both preventing and treating various gastrointestinal conditions, including antibiotic-induced side effects such as diarrhea, which may in turn increase medication tolerability and patient compliance.

Probiotics are defined by the World Health Organization (WHO) and the Food and Agriculture Organization (FAO) as living microorganisms that could potentially benefit health. Although a variety of different probiotic species have been studied, the *Lactobacillus* genus, *Bifidobacterium* genus, and *Saccharomyces* genus remain the most commonly studied. Probiotics act in numerous pathways, and both immune-mediated and nonimmune-mediated mechanisms have been documented.

Gong et al reported lower odds of *H. pylori* eradication with triple therapy alone, compared to triple therapy with probiotic supplementation (odds ratio [OR] 0.58; 95% confidence interval [CI], 0.50–0.68; *P*<0.05). Significant reductions in side effects, including nausea, vomiting, bloating, epigastric pain, diarrhea, constipation, taste distortion, and skin rash, were also observed. Numerous randomized control trials (RCTs) not included in the Gong et al study have recently been published. Furthermore, no subgroup analysis has been conducted to determine whether probiotics are beneficial in all populations, such as adults and children, as well as Asians and non-Asians.

Given the grave long-term consequences associated with chronic *H. pylori* infection, this meta-analysis provides an updated analysis on the efficacy of probiotic supplementation to triple therapy on *H. pylori* eradication rates in both children and adults, as well as the Asian and non-Asian populations.

**Methods**

**Study selection**

A comprehensive literature search of PubMed, Cochrane Central Registry of Controlled Trials, and Google Scholar from the time of inception (1966) to the present day (2016) was conducted to identify all published RCTs evaluating the effect of probiotic supplementation on the efficacy of standard triple therapy in the treatment of *H. pylori*. Using the yielded search results, additional references and studies were searched. The last search was performed on February 22, 2016. Combinations of the keywords “probiotics”, “triple therapy”, “*Campylobacter pylori*”, “*Helicobacter pylori*”, and “*H. pylori*” were used. Studies comparing the use of probiotics and
standard triple therapy with standard triple therapy alone for any duration in patients of any age diagnosed with \textit{H. pylori} infection were included. If there were duplicate publications of the same study, only the most updated and comprehensive data set for the study was included.

**Data extraction**

Each article retrieved from the database searches as described earlier was reviewed and assessed for eligibility and study inclusion. Data related to the patients, comparison groups (probiotic and standard triple therapy group vs standard triple therapy alone group), clinical outcomes, and study methodology were extracted (Figure 1). The incidence rates of \textit{H. pylori} eradication (detected via urea breath test or stool antigen) and adverse events (including nausea, vomiting, diarrhea, and epigastric pain) were assessed.

**Statistical analysis**

Relative risk (RR) along with a 95\% CI for the incidence of \textit{H. pylori} eradication and medication side effects was calculated for each included study. If any study reported a zero incidence in either the intervention (standard triple therapy and probiotic) or the control (standard triple therapy alone) group, a “0.5” continuity correction factor was applied to allow for calculation of RR and variance. Depending on the heterogeneity of the included study, either a fixed-effects model or a random-effects model was used. Both Cochrane’s \textit{Q} statistic and \textit{F} statistic were used to assess heterogeneity, and a \textit{P}<0.05 or \textit{I}\textsuperscript{2}>50 was utilized for determining the presence of significant heterogeneity. Data were analyzed using a random-effects model when heterogeneity was deemed significant, while a fixed-effects model was used in the absence of heterogeneity. Sensitivity analysis to determine the influence of each individual included study on the overall effect size (RR estimates) was assessed by removing each study one-by-one and calculating the overall effect sizes. Publication bias for the pooled \textit{H. pylori} eradication rates was evaluated, both visually using a funnel plot and quantitatively using Egger’s and Begg’s tests. Subgroup analysis was performed to determine any differences based on probiotic genus (\textit{Lactobacillus}, \textit{Bifidobacterium}, \textit{Saccharomyces}, and mixed), patient age (children vs adults), ethnicity (Asians vs non-Asians), as well as the control group utilized (placebo vs no treatment). All meta-analyses of pooled study data were conducted using Comprehensive Meta-Analysis Software Version 3 (Biostat, Englewood, NJ, USA), and statistical significance was accepted at a level of \textit{P}<0.05 (two tail).

**Results**

A total of 30 RCTs meeting the inclusion criteria were identified (Table 1). There were 4,302 patients when analyzed
Table 1 Characteristics of all published randomized control trials evaluating the use of probiotic supplementation on standard triple therapy in *Helicobacter pylori* eradication (1966–2016)

| Study                          | Antibiotic regimen and duration | Probiotic                          | Method of diagnosing *H. pylori* | Method of detecting *H. pylori* eradication | Age       | Country   |
|-------------------------------|---------------------------------|------------------------------------|----------------------------------|-------------------------------------------|-----------|-----------|
| Akcam et al<sup>19</sup>      | Lansoprazole, clarithromycin, amoxicillin (14 days) | *L. acidophilus, L. casei, Bifidobacterium* | Histology                       | UBT                                       | Children  | Turkey    |
| Bin et al<sup>20</sup>        | Omeprazole, clarithromycin, amoxicillin (or metronidazole) (14 days) | *S. boulardii*                     | Serology, histology              | UBT                                       | Children  | China     |
| Hauser et al<sup>21</sup>     | Omeprazole or pantoprazole, clarithromycin, amoxicillin (or metronidazole) (14 days) | *L. rhamnosus GG, Bifidobacterium* | Histology, UBT, stool antigen    | Rapid urease test, UBT, or stool antigen  | Adults    | Croatia   |
| Ma et al<sup>22</sup>         | Omeprazole, clarithromycin, metronidazole (7 days) | *L. acidophilus*                   | Histology, UBT, histology union of ulcer | Adults                                    | China     |
| Emara et al<sup>23</sup>      | Omeprazole, clarithromycin, amoxicillin (14 days) | *L. reuteri*                       | Stool antigen, histology         | Adults                                    | Egypt     |
| Francavilla et al<sup>24</sup> | PPI, clarithromycin, amoxicillin (7 days) | *L. reuteri*                       | UBT, serology of gastrin-17, histology | Adults                                    | Italy     |
| Srinarong et al<sup>25</sup>  | Lansoprazole, clarithromycin, amoxicillin, bismuth (7 or 14 days) | *B. lactis, L. acidophilus, L. paracasei* | Histology                        | UBT                                       | Adults    | Thailand  |
| Wang et al<sup>26</sup>       | PPI, clarithromycin, amoxicillin (or metronidazole) (14 days) | *L. acidophilus, B. bifidum*       | UBT                             | Children                                  | China     |
| Navarro-Rodriguez et al<sup>27</sup> | Lansoprazole, furazolidone, tetracycline (7 days) | *L. acidophilus, L. rhamnosus, B. bifidum, S. faecium* | UBT and histology                | UBT or histology                         | Adults    | Brazil    |
| Du et al<sup>28</sup>         | Omeprazole, clarithromycin, amoxicillin (7 days) | *L. acidophilus*                   | UBT and histology                | Adults                                    | China     |
| Mirzaee and Rezahosseini<sup>29</sup> | Pantoprazole, clarithromycin, amoxicillin (7 days) | Probiotic yogurt                   | UBT                             | Adults                                    | Iran      |
| Bekar et al<sup>30</sup>      | Lansoprazole, clarithromycin, amoxicillin (14 days) | Kefir                              | UBT                             | Adults                                    | Turkey    |
| Deguchi et al<sup>31</sup>    | Rabeprazole, clarithromycin, amoxicillin (7 days) | Yogurt – *L. gasseri*              | Histology, culture              | UBT and stool antigen                     | Adults    | Japan     |
| Medeiros et al<sup>32</sup>   | Esomeprazole, clarithromycin, amoxicillin (8 days) | *L. acidophilus*                   | Histology                        | UBT                                       | Adults    | Portugal  |
| Song et al<sup>33</sup>       | Omeprazole, clarithromycin amoxicillin (7 days) | *S. boulardii*                     | Histology                        | UBT                                       | Adults    | Korea     |
| Yasar et al<sup>34</sup>      | Pantoprazole, clarithromycin, amoxicillin (7 days) | *Bifidobacterium*                  | Histology                        | UBT                                       | Adults    | Turkey     |
| Hurduc et al<sup>35</sup>     | Omeprazole or esomeprazole, clarithromycin, amoxicillin (7–10 days) | *S. boulardii*                     | Histology                        | Adults                                    | Romania   |
| Szajewska et al<sup>36</sup>  | Omeprazole, clarithromycin, amoxicillin (7 days) | *L. rhamnosus GG*                  | UBT, histology, rapid urease test | UBT                                       | Children  | Poland    |

(Continued)
Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 207.241.231.48 on 23-Sep-2017
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Table I (Continued)

| Study       | Antibiotic regimen and duration | Probiotic                          | Method of diagnosing H. pylori | Method of detecting H. pylori eradication | Age      | Country     |
|-------------|---------------------------------|------------------------------------|-------------------------------|-------------------------------------------|----------|-------------|
| Kim et al11 | PPI, clarithromycin, amoxicillin (7 days) | L. acidophilus, L. casei, B. longum, S. thermophilus | UBT, histology, rapid urease test | UBT                                        | Adults   | Korea       |
| Scaccianoce et al12 | Lansoprazole, clarithromycin, amoxicillin (7 days) | L. reuteri, L. plantarum, L. casei, B. infantis, B. longum, L. salivarius, L. acidophilus, S. thermophilus, L. sporogenes | Histology                      | UBT                                        | Adults   | Italy       |
| Cindoruk et al13 | Lansoprazole, clarithromycin, amoxicillin (14 days) | S. boulardii                      |                                | UBT                                        | Adults   | Turkey      |
| Goldman et al14 | Omeprazole, clarithromycin, amoxicillin (7 days) | B. animalis                      | Histology, UBT                 | UBT                                        | Children | Argentina   |
| Ziemniak15 | PPI, clarithromycin, amoxicillin (10 days) | L. acidophilus, L. rhamnosus      | History and UBT                | UBT                                        | Adults   | Poland      |
| Myllyluoma et al16 | Lansoprazole, clarithromycin, amoxicillin (7 days) | L. rhamnosus GG, L. rhamnosus, P. freudenreichii, B. breve | Rapid whole blood test, UBT, serology | UBT                                        | Adults   | Finland     |
| Sykora et al17 | Omeprazole, clarithromycin amoxicillin (7 days) | L. casei                          | History, rapid urease test, culture, stool antigen | UBT, stool antigen                          | Children | Czech Republic |
| Nista et al18 | Rabeprazole, clarithromycin, amoxicillin (7 days) | B. clausii                        | UBT                            | UBT                                        | Adults   | Italy       |
| Cremonini et al19 | Rabeprazole, tinidazole, amoxicillin (7 days) | L. rhamnosus GG, S. boulardii, L. acidophilus | UBT                            | UBT                                        | Adults   | Italy       |
| Sheu et al20 | Lansoprazole, clarithromycin, amoxicillin (7 days) | Lactobacillus, Bifidobacterium | History and rapid urease test | UBT                                        | Adults   | Taiwan      |
| Armuzzi et al21 | Pantoprazole, tinidazole clarithromycin (7 days) | L. rhamnosus GG                  | UBT, IgG antibodies            | UBT                                        | Adults   | Italy       |
| Canducci et al22 | Rabeprazole, clarithromycin, amoxicillin (7 days) | L. acidophilus                    | UBT, histology                 | UBT                                        | Adults   | Italy       |

Abbreviations: B. Bifidobacterium; L. Lactobacillus; P. Propionibacterium; PPI, proton-pump inhibitor; S. Saccharomyces; UBT, urea breath test.

as-per-protocol (APP) and 4,515 patients when analyzed intention-to-treat (ITT).

Effects of probiotics on triple therapy efficacy in H. pylori eradication rates (APP treated)

All studies reported on H. pylori eradication rates in both the probiotic-supplemented and triple therapy alone groups. The addition of probiotics to the triple therapy regimen significantly increased eradication rates compared to triple therapy alone (1,786/2,140 [83.5%] vs 1,602/2,162 [74.1%]). No significant heterogeneity between trials (P=0.321, I²<8.993) was found, and a fixed-effects model was therefore utilized. There was a 12.2% increase in eradication rates with probiotic supplementation (RR=1.122; 95% CI, 1.091–1.153; P<0.001) (Figure 2).

Subgroup analysis by patient age revealed that probiotic supplementation improved the efficacy of triple therapy in both children (RR=1.176; 95% CI, 1.050–1.317; P=0.005) and adults (RR=1.118; 95% CI, 1.087–1.150; P<0.001) with no significant between group heterogeneity (P=0.491).

Subgroup analysis by the type of probiotic identified benefit for Lactobacillus (RR=1.142; 95% CI, 1.084–1.203; P<0.001), Saccharomyces (RR=1.088; 95% CI, 1.022–1.158; P=0.008), and mixture of probiotics (RR=1.135; 95% CI, 1.089–1.181; P=0.001). A trend toward an increase in eradication rates with Bifidobacterium (RR=1.094; 95% CI, 0.992–1.207; P=0.073) was also observed. There was no significant between group heterogeneity (P=0.589).

Subgroup analysis by ethnicity identified that probiotic supplementation improved the efficacy of triple therapy in both Asians (RR=1.108; 95% CI, 1.066–1.152; P<0.001) and non-Asians (RR=1.136; 95% CI, 1.074–1.203; P<0.001), with no statistically significant between group differences (P=0.826).
Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 207.241.231.48 on 23-Sep-2017
For personal use only.

Abbreviation: CI, confidence interval; L, Lactobacillus; S, Saccharomyces; M, mixture of probiotics.

| Study name           | Risk ratio | Lower limit | Upper limit | P-value  | Relative weight |
|----------------------|------------|-------------|-------------|----------|----------------|
| Akcam et al58        | 0.967      | 0.673       | 1.388       | 0.854    | 0.58           |
| Bin et al56          | 1.154      | 0.750       | 1.775       | 0.515    | 12.16          |
| Hauser et al37       | 1.204      | 1.113       | 1.303       | 0.000    | 1.84           |
| Ma et al38           | 1.381      | 1.127       | 1.692       | 0.002    | 0.80           |
| Emar et al39         | 1.130      | 0.830       | 1.539       | 0.436    | 1.08           |
| Francavilla et al50  | 1.138      | 0.873       | 1.483       | 0.339    | 12.06          |
| Srinarong et al11    | 1.063      | 0.982       | 1.151       | 0.130    | 1.18           |
| Wang et al31         | 1.299      | 1.008       | 1.675       | 0.043    | 3.45           |
| Navarro-Rodriguez et al19 | 1.053 | 0.908       | 1.221       | 0.498    | 2.05           |
| Du et al42           | 1.350      | 1.113       | 1.636       | 0.002    | 0.57           |
| Mirzaee and Rezahasem43 | 1.839      | 0.583       | 1.207       | 0.344    | 4.17           |
| Bekar et al44        | 1.565      | 1.092       | 2.244       | 0.015    | 0.58           |
| Deguchi et al45      | 1.148      | 1.003       | 1.314       | 0.045    | 14.20          |
| Medeiros et al46     | 1.040      | 0.825       | 1.311       | 0.740    | 0.53           |
| Song et al47         | 1.067      | 0.992       | 1.148       | 0.082    | 2.53           |
| Yasar et al49        | 1.250      | 0.856       | 1.626       | 0.248    | 0.70           |
| Hurduc et al50       | 1.158      | 0.983       | 1.364       | 0.079    | 7.62           |
| Szajewska et al50    | 0.984      | 0.708       | 1.368       | 0.923    | 0.23           |
| Kim et al51          | 1.112      | 1.007       | 1.229       | 0.036    | 0.22           |
| Scaccianoce et al52 (L) | 0.794   | 0.448       | 1.409       | 0.431    | 12.42          |
| Scaccianoce et al52 (M) | 0.800   | 0.442       | 1.448       | 0.461    | 1.31           |
| Cindoruk et al53     | 1.189      | 0.918       | 1.541       | 0.190    | 0.17           |
| Goldman et al54      | 1.212      | 0.677       | 2.171       | 0.518    | 1.56           |
| Ziemniak55           | 1.120      | 1.035       | 1.211       | 0.005    | 0.72           |
| Mylllyuoma et al56   | 1.153      | 0.906       | 1.467       | 0.246    | 0.97           |
| Sykora et al57       | 1.494      | 1.158       | 1.926       | 0.002    | 7.33           |
| Nista et al58        | 1.054      | 0.845       | 1.314       | 0.640    | 1.32           |
| Cremonini et al15 (L) | 0.952   | 0.689       | 1.317       | 0.768    | 2.23           |
| Cremonini et al15 (S) | 1.063      | 0.798       | 1.415       | 0.678    | 11.41          |
| Cremonini et al15 (M) | 1.071      | 0.810       | 1.418       | 0.629    | 1.092          |
| Sheu et al59         | 1.083      | 0.979       | 1.200       | 0.122    | 0.58           |
| Armuzi et al60       | 1.042      | 0.819       | 1.324       | 0.739    | 1.015          |
| Canducci et al61     | 1.217      | 1.012       | 1.464       | 0.037    | 0.41           |
| Overall              | 1.122      | 1.091       | 1.153       | 0.000    | 14.20          |

Figure 2 Forest plot evaluating the relative risk of Helicobacter pylori eradication associated with probiotic supplementation (as-per-protocol treated).
Abbreviation: CI, confidence interval; L, Lactobacillus; S, Saccharomyces; M, mixture of probiotics.

Subgroup analysis based on the type of control group utilized revealed a significant improvement in triple therapy efficacy in both the no treatment group (RR =1.152; 95% CI, 1.106–1.200; P<0.001) and placebo group (RR =1.122; 95% CI, 1.075–1.170; P<0.001), with no significant difference between the two groups (P=0.365).

Effects of probiotics on triple therapy efficacy in H. pylori eradication rates (ITT)

The addition of probiotics to the triple therapy regimen significantly increased eradication rates compared to triple therapy alone (1,744/2,222 [78.5%] vs 1,564/2,293 [68.2%]). Heterogeneity between trials was deemed not significant (P=0.459, F<0.445), and therefore a fixed-effects model was employed. There was a 14.1% increase in eradication rates with the addition of probiotics (RR =1.141; 95% CI, 1.106–1.176; P<0.001) (Figure 3).

Subgroup analysis based on patient age showed that probiotic supplementation improved the efficacy of triple therapy in both children (RR =1.193; 95% CI, 1.106–1.176; P<0.001) and adults (RR =1.138; 95% CI, 1.102–1.174; P<0.001), with no significant between group heterogeneity (P=0.557).

Subgroup analysis based on the type of probiotic identified benefit for Lactobacillus (RR =1.153; 95% CI, 1.092–1.217; P<0.001), Bifidobacterium (RR =1.168; 95% CI, 1.031–1.324; P=0.015), Saccharomyces (RR =1.127; 95% CI, 1.050–1.211; P=0.001), and mixture of probiotics (RR =1.140; 95% CI, 1.086–1.197; P<0.001). There was no significant difference in heterogeneity between the groups (P=0.938).
Subgroup analysis by ethnicity identified that probiotic supplementation improved the efficacy of triple therapy in both Asians (RR =1.132; 95% CI, 1.084–1.182; P<0.001) and non-Asians (RR =1.150; 95% CI, 1.101–1.200; P<0.001), with no significant difference based on ethnicity (P=0.959).

Subgroup analysis of the control group utilized identified a significant improvement in triple therapy efficacy in both the no treatment group (RR =1.149; 95% CI, 1.103–1.197; P<0.001) and placebo group (RR =1.130; 95% CI, 1.079–1.184; P<0.001), with no significant difference between the two groups (P=0.636).

**Adverse events**

A total of 18 of the studies (N=2,916 patients) reported on the incidence of vomiting, 19 of the studies (N=2,554 patients) reported on the incidence of diarrhea, and 14 of the studies (N=2,537 patients) reported on the incidence of epigastric pain. There was a significant reduction in the risk of nausea (RR =0.606; 95% CI, 0.520–0.705; P<0.001), vomiting (RR =0.724; 95% CI, 0.533–0.985; P=0.040), diarrhea (RR =0.549; 95% CI, 0.391–0.771; P=0.001), and epigastric pain (RR =0.812; 95% CI, 0.727–0.907; P<0.001) with the addition of probiotics to standard triple therapy compared to triple therapy alone (Figures S1–S4).

**Sensitivity analysis**

Sensitivity analysis revealed similar overall effect sizes and RR estimates for *H. pylori* eradication rates after the removal of each individual study. *H. pylori* eradication rates ranged from 11.1% increase (RR =1.111; 95% CI, 1.078–1.144;
Infection and Drug Resistance downloaded from https://www.dovepress.com/ by 207.241.231.48 on 23-Sep-2017
For personal use only.
Powered by TCPDF (www.tcpdf.org)

Lau et al

Discussion

*H. pylori*, a Gram-negative, spiral bacterium, was first discovered in 1982 by Warren and Marshall.1 Over half of the world’s population is colonized with *H. pylori*, which if left untreated potentially leads to chronic gastritis, gastric and duodenal ulcers, gastric cancer, and MALTomas.2,4,5,7,22

Chronic inflammation leads to the production of reactive oxygen species (ROS), leading to DNA damage, causing damage to the epithelium and atrophy of the gastric lining.2 Chronic inflammation leads to mutations, intestinal metaplasia and loss of gastric acid secretion, and reactive oxygen species (ROS), leading to DNA damage, causing damage to the epithelium and atrophy of the gastric lining.2 Chronic inflammation leads to the production of and further gastric pathology.2

Standard triple therapy remains the gold standard for eradicating *H. pylori*; however, more recent studies have shown a constant decline in *H. pylori* eradication rates, to as low as 50%.12,23,24 This decline has been attributed to increased clarithromycin resistance and low medication compliance secondary to medication side effects.13,14 Numerous alternative therapeutic regimens to enhance eradication rates have been proposed, including sequential therapy, which utilizes a dual 5-day regimen of amoxicillin and an initial 5-day regimen of amoxicillin and a proton pump inhibitor followed by 5 days of clarithromycin, metronidazole, and a proton pump inhibitor.25 Lau et al25 conducted a meta-analysis with 12 RCTs and 1,221 patients and revealed that sequential therapy improved eradication rates by 14.2%. Low medication compliance due to side effects has been deemed the most important factor in eradicating *H. pylori*, highlighting the need for novel treatments that increase medication tolerability and patient compliance.17

Probiotics, living commensal microorganisms naturally found in the host intestinal flora, exert a protective effect on the gastrointestinal tract.26,27 Although the precise mechanism of probiotics has not been fully elucidated, numerous mechanisms have been proposed. Each probiotic strain has a unique mechanism of action that may be more or less effective in increasing *H. pylori* eradication and reducing the side effects. Previous studies have shown that probiotics significantly reduce the risk of antibiotic-associated side effects, including nausea, vomiting, diarrhea, and epigastric pain.24,26 These commensal bacteria inhibit enteric pathogens and suppress pathogenic bacterial growth and invasion, ultimately improving intestinal barrier function.28 Probiotics also modulate proinflammatory cytokines, which help maintain homeostasis and regulate immune responses.28,29 *Lactobacillus* species have been shown to modify immune response by decreasing the levels of proinflammatory cytokines, stimulate mucosecretion, suppress bacterial growth, and inhibit *H. pylori* adhesion to the gastric epithelium.14,20 Studies have shown that *Lactobacillus salivarius* reduces interleukin (IL)-8 secretion from the gastric epithelial cells, *Lactobacillus acidophilus* inactivates the Smad7 and NFKβ inflammatory pathways, and *Lactobacillus bulgaricus* inhibits the activation of the TLR4 signaling pathway and IL-8 production.20 *Lactobacilli* are also able to enhance the local IgA secretion and reduce specific anti-*H. pylori* IgG antibodies.20 Additionally, strains of *Lactobacillus* are responsible for increasing mucin production.20 Mucins protect the gastric epithelium, and *H. pylori* suppresses MUC5AC and MUC1 gene expressions. *Lactobacillus plantarum* 299v increases MUC2 expression while *Lactobacillus rhamnosus* GG stimulates MUC3 gene expression.20 *Lactobacilli* also secrete antibacterial substances, including lactic acid, hydrogen peroxidase, bactericines, and short-chain fatty acids.14,20 *L. acidophilus* contains an autolysin, a proteinaceous compound, and antibacterial that is released after the cell lyses.20 *Lactobacillus reuteri* produces reuterina that suppresses the growth of bacteria and also inhibits bacterial adhesion and colonization by binding of spiral bacterium to glycolipid protein receptors asialo-GMI and sulfatide.20 *Bifidobacterium* acts by inhibiting DNA gyrase enzymes involved in bacterial cell division.20 *Saccharomyces* contains neuroaminidase activity that removes the ligand for sialic acid-binding *H. pylori* adhesion to the gastric epithelium, α(2-3)-linked sialic acid.20

This current meta-analysis found that the addition of probiotics to the triple therapy is associated with a 13.8% increase in the chance of eradicating *H. pylori* infection compared to triple therapy alone, which is consistent with the results of a prior meta-analysis.21 Additionally, probiotics have shown a significant decrease in side effects, including nausea, vomiting, epigastric pain, and diarrhea.

Despite the improvements in *H. pylori* eradication with adjunct probiotics, the use of probiotics as monotherapy has been shown to reduce bacterial load but not effective in
eradicating \textit{H. pylori}. Bhatia et al discovered that \textit{H. pylori} growth was inhibited in vitro if \textit{L. acidophilus} was present. Michetti et al was the first to study the effect of \textit{L. acidophilus} in vivo, concluding that the probiotic decreased the density of the bacterial load, but complete eradication was unsuccessful. Wang et al studied adult patients taking multispecies probiotic therapies that included \textit{L. acidophilus} and concluded a decrease in urea breath test values but not in complete \textit{H. pylori} eradication.

Although probiotic efficacy has been studied extensively with numerous RCTs, the side effect profile for probiotics is not well documented. The Agency for Healthcare Research and Quality conducted a comprehensive review of 622 studies on the safety of probiotic use, and reported that a majority of the published studies only state the presence or absence of one or more specific side effect, but lack specific details, and only a third provided vague statements indicating that the probiotics were well tolerated. Case reports of sepsis, bacteremia, and fungemia with probiotic use have been reported; however, these adverse events are inconsistent and, when pooled together, are not statistically significant.

Despite the significant and positive results from this meta-analysis, there are several limitations, mainly a result of the variation and heterogeneity of the included RCTs. Age, gender, ethnicity, and country of origin varied. The specific medications and dosage regimen, as well as diagnostic methods and any follow-up conducted, varied between studies. Similarly, the specific probiotic strain, dose, and treatment duration utilized were also slightly different. Additional RCTs are required to determine the best probiotic supplement for \textit{H. pylori} eradication. Given the promise of probiotics in \textit{H. pylori} eradication, further studies evaluating the bactericidal effects of different probiotic strains and potentially comparing the efficacy of probiotics alone vs probiotics in combination with triple therapy are warranted.

Despite the limitations discussed, this study identified that probiotic supplementation is associated with increased \textit{H. pylori} eradication rates in adults and children, as well as Asians and non-Asians, compared to standard triple therapy alone. \textit{Lactobacillus}, \textit{Bifidobacterium}, \textit{Saccharomyces}, and mixtures of probiotics appear beneficial in \textit{H. pylori} eradication. Furthermore, the reduction in antibiotic-associated side effects, such as nausea, vomiting, diarrhea, and epigastric pain, improves medication tolerance and patient compliance. Given the significant increase in \textit{H. pylori} eradication rate and reduction in side effects, probiotics should be administered concurrently with standard triple therapy.

\section*{Acknowledgments}

The abstract of this study was presented at the Digestive Disease Week conference (May 21–24, 2016, San Diego, CA, USA) as a poster presentation with interim findings. The poster abstract was published in “Poster Abstracts” in \textit{Gastroenterology} (Volume 150, Issue 4, Supplement 1, Page S878).

\section*{Disclosure}

The authors report no conflicts of interest in this work and have not accepted financial sponsorship in producing and presenting this article.

\section*{References}

1. Brown LM. \textit{Helicobacter pylori}: epidemiology and routes of transmission. \textit{Epidemiol Rev.} 2000;22(2):283–297.
2. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of \textit{Helicobacter pylori} infection. \textit{Clin Microbiol Rev.} 2006;19(3):449–490.
3. Goni E, Franceschi F. \textit{Helicobacter pylori} and extragastric diseases. \textit{Helicobacter.} 2016;21(suppl 1):45–48.
4. Nomura A, Stammernmann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. \textit{Helicobacter pylori} infection and gastric carcinoma among Japanese Americans in Hawaii. \textit{N Engl J Med.} 1991;325(16):1132–1136.
5. Nomura A, Stammernmann GN, Chyou PH, Perez-Perez GI, Blaser MJ. \textit{Helicobacter pylori} infection and the risk for duodenal and gastric ulceration. \textit{Ann Intern Med.} 1994;120(12):977–981.
6. Rauws EA, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GN. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiluculent treatment. \textit{Gastroenterology.} 1988;94(1):33–40.
7. Eidt S, Stolte M, Fischer R. \textit{Helicobacter pylori} gastritis and primary gastric non-Hodgkin’s lymphomas. \textit{J Clin Pathol.} 1994;47(5):436–439.
8. Hung IF, Wong BC. Assessing the risks and benefits of treating \textit{Helicobacter pylori} infection. \textit{Therap Adv Gastroenterol.} 2009;2(3):141–147.
9. Bazzoli F, Pozzato P. Therapy of \textit{H. pylori} infection. \textit{J Physiol Pharmacol.} 1997;48(suppl 4):39–46.
10. Papastergiou V, Georgopoulos SD, Karatanapis S. Treatment of \textit{Helicobacter pylori} infection: past, present and future. \textit{World J Gastrointest Pathophysiol.} 2014;5(4):392–399.
11. Lind T, Veldhuyzen van ZS, Unger P, et al. Eradication of \textit{Helicobacter pylori} using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. \textit{Helicobacter.} 1996;1(3):138–144.
12. Kutuk G, Tutor E, Bayrak A, et al. Sequential therapy versus standard triple therapy for \textit{Helicobacter pylori} eradication in children: any advantage in clarithromycin-resistant strains? \textit{Eur J Gastroenterol Hepatol.} 2014;26(11):1202–1208.
13. Megraud F, Doernman HP. Clinical relevance of resistant strains of \textit{Helicobacter pylori}: a review of current data. \textit{Gut.} 1998;43(suppl 1):S61–S65.
14. Ruggiero P. Use of probiotics in the fight against \textit{Helicobacter pylori}. \textit{World J Gastrointest Pathophysiol.} 2014;5(4):384–391.
15. Cremonini F, Di CS, Covino M, et al. Effect of different probiotic preparations on anti-\textit{Helicobacter pylori} therapy-related side effects: a parallel group, triple blind, placebo-controlled study. \textit{Am J Gastroenterol.} 2002;97(11):2744–2749.
16. Venerito M, Krieger T, Ecker T, Leandro G, Malfertheiner P. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of \textit{Helicobacter pylori} infection. \textit{Digestion.} 2013;88(1):33–45.
17. O’Connor JP, Taneike I, O’Morain C. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol. 2009;2(5):273–279.
18. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992;102(2):493–496.
19. Navarro-Rodriguez T, Silva FM, Barbuti RC, et al. Association of a probiotic to a Helicobacter pylori pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013;13:56.
20. Homan M, Orel R. Are probiotics useful in Helicobacter pylori eradication? World J Gastroenterol. 2015;21(37):10644–10653.
21. Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(4):6530–6543.
22. Dooley CP, Cohen H, Fitzgibbon PL, et al. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med. 1989;321(23):1562–1566.
23. Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology. 2005;129(5):1414–1419.
24. Huang J, Zhou L, Geng L, et al. Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-label study. Aliment Pharmacol Ther. 2013;38(10):1230–1235.
25. Lau CS, Ward A, Chamberlain RS. Sequential (as Compared to Simultaneous) antibiotic therapy improves Helicobacter pylori eradication in the pediatric population: a meta-analysis. Clin Pediatr (Phila). 2016;55(7):614–625.
26. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):1959–1969.
27. Lau C, Chamberlain RS. Probiotics are effective at preventing Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Int J Gen Med. 2016;9:27–37.
28. Rohde CL, Bartolini V, Jones N. The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea. Nutr Clin Pract. 2009;24(1):33–40.
29. Jones SE, Versalovic J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. BMC Microbiol. 2009;9:35.
30. Namkin K, Zardast M, Basirinejad F. Saccharomyces boulardii in Helicobacter Pylori eradication in children: a randomized trial from Iran. Iran J Pediatr. 2016;26(1):e3768.
31. Wang KY, Li SN, Liu CS, et al. Effects of ingesting Lactobacillus- and Bifidobacterium-containing yogurt in subjects with colonized Helicobacter pylori. Am J Clin Nutr. 2004;80(3):737–741.
32. Bhatta SJ, Kochar N, Abraham P, Nair NG, Mehta AP. Lactobacillus acidophilus inhibits growth of Campylobacter pylori in vitro. J Clin Microbiol. 1989;27(10):2328–2330.
33. Michetti P, Duron G, Wiesel PH, et al. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnssoni) L1 on Helicobacter pylori infection in humans. Digestion. 1999;60(3):203–209.
34. Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2011:1–645.
35. Akcam M, Koca T, Salman H, Karahan N. The effects of probiotics on treatment of Helicobacter pylori eradication in children. Saudi Med J. 2015;36(3):286–290.
36. Bin Z, Ya-Zheng X, Zhao-Hui D, Bo C, Li-Rong J, Vandenplas Y. The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in children. Pediatr Gastroenterol Hepatol Nutr. 2015;18(1):17–22.
37. Hauser G, Salkic N, Vukelic K, JajacKnez A, Stimac D. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. Medicine (Baltimore). 2015;94(17):e685.
38. Ma F, Zhou C, Wang J, Liu T, Liu J. Probiotics in the treatment of peptic ulcer infected by helicobacter pylori and its safety. Pak J Pharm Sci. 2015;28(3 suppl):1087–1090.
39. Emara MH, Mohamed SY, Abdel-Aziz HR. Lactobacillus reuteri in management of Helicobacter pylori pylori infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. Therap Adv Gastroenterol. 2014;7(1):1–13.
40. Francavilla R, Polimeno L, Demichina A, et al. Lactobacillus reuteri strain combination in Helicobacter pylori pylori infection: a randomized, double-blind, placebo-controlled study. J Clin Gastroenterol. 2014;48(5):407–413.
41. Srinarong C, Siramolpiwat S, Wongcha-um A, Mahachat Vilaichek RK. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori pylori treatment in Thailand. Asian Pac J Cancer Prev. 2014;15(22):9909–9913.
42. Du YQ, Su T, Fan JG, et al. Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori pylori infection. World J Gastroenterol. 2012;18(43):6302–6307.
43. Mirzae V, Rezahoseini O. Randomized control trial: comparison of triple therapy plus probiotic yogurt vs. standard triple therapy on Helicobacter pylori pylori eradication. Iran Red Crescent Med J. 2012;14(10):657–666.
44. Bekar O, Yilmaz Y, Gulten M. Kefir improves the efficacy and tolerability of triple therapy in eradicating Helicobacter pylori. J Med Food. 2011;14(4):344–347.
45. Deguchi R, Nakaminami H, Rimbara L, et al. Evaluation of Helicobacter pylori pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone. Eur J Clin Microbiol Infect Dis. 2011;30(4):555–559.
46. Song MJ, Park DI, Park JH, et al. The effects of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010;15(3):206–213.
47. Yasar B, Abut E, Kayadibi H, et al. Efficacy of probiotics in Helicobacter pylori pylori eradication therapy. Turk J Gastroenterol. 2010;21(3):212–217.
48. Hurduc V, Plesca D, Dragomir D, Sajin M, Vandendris P. A randomized, open trial evaluating the effect of Saccharomyces boulardii on the eradication rate of Helicobacter pylori pylori in children. Acta Paediatr. 2009;98(1):127–131.
49. Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled study: effect of Lactobacillus GG double supplementation on Helicobacter pylori pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48(4):431–436.
50. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori pylori eradication. Helicobacter. 2008;13(4):261–268.
51. Scaccianoce G, Zullo A, Hassain C, et al. Triple therapies plus different probiotics for Helicobacter pylori pylori eradication. Eur Rev Med Pharmacol Sci. 2008;12(4):251–256.
52. Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12(4):309–316.
53. Goldman CG, Barrado DA, Balcarce N, et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori pylori infection in children. Nutrition. 2006;22(10):984–988.
54. Zieniaiic W. Efficacy of Helicobacter pylori pylori eradication taking into account its resistance to antibiotics. J Physiol Pharmacol. 2006;57(suppl 3):123–141.
56. Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to *Helicobacter pylori* eradication therapy – a placebo-controlled, double-blind randomized pilot study. *Aliment Pharmacol Ther*. 2005;21(10):1263–1272.

57. Sykora J, Valeckova K, Amlerova J, et al. Effects of a specially designed fermented milk product containing probiotic *Lactobacillus casei* DN-114 001 and the eradication of *H. pylori* in children: a prospective randomized double-blind study. *J Clin Gastroenterol*. 2005;39(8):692–698.

58. Nista EC, Candelli M, Cremonini F, et al. Bacillus clausii therapy to reduce side-effects of anti-*Helicobacter pylori* treatment: randomized, double-blind, placebo controlled trial. *Aliment Pharmacol Ther*. 2004;20(10):1181–1188.

59. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with *Lactobacillus*- and *Bifidobacterium*-containing yogurt on triple therapy for *Helicobacter pylori* eradication. *Aliment Pharmacol Ther*. 2002;16(9):1669–1675.

60. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of *Lactobacillus GG* on antibiotic-associated gastrointestinal side-effects during *Helicobacter pylori* eradication therapy. *Aliment Pharmacol Ther*. 2001;15(2):163–169.

61. Canducci F, Armuzzi A, Cremonini F, et al. A lyophilized and inactivated culture of *Lactobacillus acidophilus* increases *Helicobacter pylori* eradication rates. *Aliment Pharmacol Ther*. 2000;14(12):1625–1629.
Supplementary Materials

**Figure S1** Forest plot evaluating the relative risk of nausea associated with probiotic supplementation.

**Abbreviations:** CI, confidence interval; L, Lactobacillus; S, Saccharomyces; M, mixture of probiotics.

| Study name            | Statistics for each study | Risk ratio and 95% CI | Relative weight |
|-----------------------|---------------------------|-----------------------|-----------------|
|                       | Risk ratio | Lower limit | Upper limit | P-value |                       |                       |
| Akcam et al<sup>35</sup> | 0.895     | 0.309      | 2.596      | 0.838    | 2.03                  |                       |
| Hauser et al<sup>37</sup> | 0.628     | 0.515      | 0.767      | 0.001    | 58.37                 |                       |
| Francavilla et al<sup>40</sup> | 0.400     | 0.082      | 1.951      | 0.257    | 0.92                  |                       |
| Srinarong et al<sup>41</sup> | 0.917     | 0.447      | 1.880      | 0.812    | 4.47                  |                       |
| Wang et al<sup>31</sup> | 0.149     | 0.008      | 2.809      | 0.204    | 0.27                  |                       |
| Bekar et al<sup>44</sup> | 0.470     | 0.233      | 0.947      | 0.035    | 4.68                  |                       |
| Song et al<sup>47</sup> | 0.716     | 0.230      | 2.235      | 0.566    | 1.78                  |                       |
| Yasar et al<sup>48</sup> | 0.556     | 0.296      | 1.042      | 0.067    | 5.83                  |                       |
| Kim et al<sup>31</sup> | 7.456     | 0.388      | 143.267    | 0.183    | 0.26                  |                       |
| Scaccianoce et al<sup>52</sup> (M) | 1.067     | 0.073      | 15.570     | 0.962    | 0.32                  |                       |
| Cindoruk et al<sup>53</sup> | 0.538     | 0.230      | 1.258      | 0.153    | 3.20                  |                       |
| Mylllyuoma et al<sup>56</sup> | 0.626     | 0.169      | 2.325      | 0.484    | 1.34                  |                       |
| Nista et al<sup>58</sup> | 0.385     | 0.222      | 0.668      | 0.001    | 7.60                  |                       |
| Cremonini et al<sup>15</sup> (L) | 0.635     | 0.118      | 3.411      | 0.596    | 0.82                  |                       |
| Cremonini et al<sup>15</sup> (S) | 0.333     | 0.038      | 2.939      | 0.323    | 0.49                  |                       |
| Cremonini et al<sup>15</sup> (M) | 0.635     | 0.118      | 3.411      | 0.596    | 0.82                  |                       |
| Sheu et al<sup>59</sup> | 0.625     | 0.214      | 1.829      | 0.391    | 2.00                  |                       |
| Armuzzi et al<sup>60</sup> | 0.300     | 0.092      | 0.983      | 0.047    | 1.64                  |                       |
| Canducci et al<sup>51</sup> | 1.000     | 0.427      | 2.344      | 1.000    | 3.18                  |                       |
| Overall               | 0.606     | 0.520      | 0.705      | 0.000    | 100                   |                       |

**Figure S2** Forest plot evaluating the relative risk of vomiting associated with probiotic supplementation.

**Abbreviations:** CI, confidence interval; L, Lactobacillus; S, Saccharomyces; M, mixture of probiotics.

| Study name            | Statistics for each study | Risk ratio and 95% CI | Relative weight |
|-----------------------|---------------------------|-----------------------|-----------------|
|                       | Risk ratio | Lower limit | Upper limit | P-value |                       |                       |
| Akcam et al<sup>35</sup> | 2.148     | 0.206      | 22.357     | 0.522    | 1.72                  |                       |
| Hauser et al<sup>37</sup> | 0.740     | 0.463      | 1.184      | 0.209    | 42.87                 |                       |
| Emara et al<sup>39</sup> | 1.000     | 0.149      | 6.707      | 1.000    | 2.61                  |                       |
| Francavilla et al<sup>40</sup> | 3.000     | 0.126      | 71.652     | 0.497    | 0.94                  |                       |
| Srinarong et al<sup>41</sup> | 0.917     | 0.447      | 1.880      | 0.812    | 18.31                 |                       |
| Wang et al<sup>31</sup> | 0.149     | 0.008      | 2.809      | 0.204    | 1.10                  |                       |
| Bekar et al<sup>44</sup> | 0.783     | 0.116      | 5.289      | 0.801    | 2.59                  |                       |
| Yasar et al<sup>48</sup> | 0.600     | 0.154      | 2.335      | 0.461    | 5.11                  |                       |
| Mylllyuoma et al<sup>56</sup> | 0.208     | 0.011      | 4.119      | 0.303    | 1.06                  |                       |
| Nista et al<sup>58</sup> | 0.321     | 0.068      | 1.519      | 0.152    | 3.91                  |                       |
| Cremonini et al<sup>15</sup> (L) | 0.318     | 0.014      | 7.383      | 0.475    | 0.96                  |                       |
| Cremonini et al<sup>15</sup> (S) | 0.333     | 0.014      | 7.724      | 0.493    | 0.96                  |                       |
| Cremonini et al<sup>15</sup> (M) | 0.318     | 0.014      | 7.383      | 0.475    | 0.96                  |                       |
| Sheu et al<sup>59</sup> | 0.143     | 0.018      | 1.135      | 0.066    | 2.20                  |                       |
| Armuzzi et al<sup>60</sup> | 0.500     | 0.048      | 5.224      | 0.563    | 1.71                  |                       |
| Canducci et al<sup>51</sup> | 1.000     | 0.427      | 2.344      | 1.000    | 13.01                 |                       |
| Overall               | 0.724     | 0.533      | 0.985      | 0.040    | 100                   |                       |
### Figure S3

Forest plot evaluating the relative risk of diarrhea associated with probiotic supplementation.

**Abbreviations:** CI, confidence interval; L, Lactobacillus; S, Saccharomyces; M, mixture of probiotics.

| Study name          | Statistics for each study | Risk ratio and 95% CI | Relative weight |
|---------------------|---------------------------|-----------------------|-----------------|
| Akcam et al\textsuperscript{35} | 2.148 0.206 22.357 0.522 | 0.522 | 1.79 |
| Hauser et al\textsuperscript{37} | 0.263 0.145 0.477 0.000 | 0.000 | 8.94 |
| Emara et al\textsuperscript{39} | 0.100 0.014 0.740 0.024 | 0.024 | 2.33 |
| Francavilla et al\textsuperscript{40} | 0.333 0.117 0.952 0.040 | 0.040 | 5.65 |
| Srinarong et al\textsuperscript{41} | 0.600 0.330 1.092 0.095 | 0.095 | 8.90 |
| Wang et al\textsuperscript{31} | 0.628 0.160 2.488 0.505 | 0.505 | 4.09 |
| Bekar et al\textsuperscript{44} | 0.478 0.260 0.880 0.018 | 0.018 | 8.81 |
| Deguchi et al\textsuperscript{45} | 1.487 0.431 5.130 0.530 | 0.530 | 4.66 |
| Yasar et al\textsuperscript{46} | 0.933 0.526 1.655 0.813 | 0.813 | 9.12 |
| Kim et al\textsuperscript{51} | 1.218 0.613 2.417 0.573 | 0.573 | 8.19 |
| Scaccianoce et al\textsuperscript{52} (M) | 1.067 0.171 6.643 0.945 | 0.945 | 2.69 |
| Cindoruk et al\textsuperscript{53} | 0.474 0.233 0.964 0.039 | 0.039 | 7.99 |
| Mylyluoma et al\textsuperscript{56} | 2.087 0.422 10.317 0.367 | 0.367 | 3.30 |
| Nista et al\textsuperscript{58} | 0.481 0.154 1.503 0.208 | 0.208 | 5.16 |
| Cremonini et al\textsuperscript{15} (L) | 0.159 0.021 1.204 0.075 | 0.075 | 2.28 |
| Cremonini et al\textsuperscript{15} (S) | 0.167 0.022 1.262 0.083 | 0.083 | 2.28 |
| Cremonini et al\textsuperscript{15} (M) | 0.159 0.021 1.204 0.075 | 0.075 | 2.28 |
| Sheu et al\textsuperscript{59} | 0.200 0.045 0.884 0.034 | 0.034 | 3.66 |
| Armuzzi et al\textsuperscript{60} | 0.125 0.017 0.939 0.043 | 0.043 | 2.30 |
| Canducci et al\textsuperscript{61} | 1.600 0.555 4.611 0.384 | 0.384 | 5.60 |
| Overall | 0.549 0.391 0.771 0.001 | 0.001 | 5.60 |

### Figure S4

Forest plot evaluating the relative risk of epigastric pain associated with probiotic supplementation.

**Abbreviations:** CI, confidence interval; L, Lactobacillus; S, Saccharomyces; M, mixture of probiotics.

| Study name          | Statistics for each study | Risk ratio and 95% CI | Relative weight |
|---------------------|---------------------------|-----------------------|-----------------|
| Akcam et al\textsuperscript{35} | 1.534 0.682 3.454 0.301 | 0.301 | 1.86 |
| Hauser et al\textsuperscript{37} | 0.859 0.751 0.982 0.026 | 0.026 | 67.66 |
| Francavilla et al\textsuperscript{40} | 0.333 0.097 1.148 0.082 | 0.082 | 0.80 |
| Bekar et al\textsuperscript{44} | 0.376 0.221 0.640 0.000 | 0.000 | 4.32 |
| Song et al\textsuperscript{47} | 1.003 0.441 2.281 0.994 | 0.994 | 1.81 |
| Yasar et al\textsuperscript{48} | 0.750 0.359 1.964 0.445 | 0.445 | 2.25 |
| Kim et al\textsuperscript{51} | 0.852 0.233 3.121 0.809 | 0.809 | 0.73 |
| Cindoruk et al\textsuperscript{53} | 0.333 0.171 0.650 0.001 | 0.001 | 2.75 |
| Mylyluoma et al\textsuperscript{56} | 0.596 0.201 1.769 0.351 | 0.351 | 1.04 |
| Nista et al\textsuperscript{58} | 0.850 0.623 1.158 0.303 | 0.303 | 12.75 |
| Cremonini et al\textsuperscript{15} (L) | 0.952 0.217 4.178 0.948 | 0.948 | 0.56 |
| Cremonini et al\textsuperscript{15} (S) | 1.000 0.229 4.373 1.000 | 1.000 | 0.56 |
| Cremonini et al\textsuperscript{15} (M) | 0.317 0.036 2.805 0.302 | 0.302 | 0.26 |
| Armuzzi et al\textsuperscript{60} | 1.111 0.528 2.340 0.782 | 0.782 | 2.21 |
| Canducci et al\textsuperscript{61} | 2.000 0.381 10.511 0.413 | 0.413 | 0.44 |
| Overall | 0.812 0.727 0.907 0.000 | 0.000 | 0.44 |
Figure S5 Sensitivity analysis evaluating the impact of removing each randomized control trial on the overall relative risk of Helicobacter pylori eradication with probiotic supplementation.  

**Abbreviations:** CI, confidence interval; L, Lactobacillus; S, Saccharomyces; M, mixture of probiotics.
Figure S6  Funnel plot assessing publication bias (analyzing the effect of probiotics on the efficacy of triple therapy in the eradication of Helicobacter pylori).

Notes: Each circle represents a RCT included in the current meta-analysis. The diamond represents the overall result.

Abbreviation: RCT, randomized control trial.